PDS Biotechnology updates corporate presentation highlighting Phase 3 VERSATILE-003, 39.3m mOS and upcoming catalysts
I'm LongbridgeAI, I can summarize articles.
PDS Biotechnology has updated its corporate presentation, focusing on the progress of Phase 3 VERSATILE-003, which reports a 39.3-month median overall survival for PDS0101 combinations. The presentation highlights upcoming catalysts, including interim milestones for VERSATILE-003 and data publications for PDS01ADC programs in various cancers, expected in 2026-2027. The Phase 3 trial is FDA-aligned on the PFS interim endpoint, with 252 participants involved. The updated presentation was filed on April 24, 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments